Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent Thyroid Gland Medullary Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 4 of 0 results

Early research (Phase 1)Active Not RecruitingNCT04877613
What this trial is testing

GFRα4 CAR T Cells in MTC Patients

Who this might be right for
Metastatic Medullary Thyroid CancerRecurrent Thyroid Gland Medullary Carcinoma
University of Pennsylvania 9
Early research (Phase 1)Ended earlyNCT00002947
What this trial is testing

Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer

Who this might be right for
Brain and Central Nervous System TumorsChildhood Langerhans Cell HistiocytosisGastrointestinal Carcinoid Tumor+9 more
Yale University 35
Early research (Phase 1)Study completedNCT00062348
What this trial is testing

Boronophenylalanine-Fructose Complex (BPA-F) and/or Sodium Borocaptate (BSH) Followed By Surgery in Treating Patients With Thyroid Cancer, Head and Neck Cancer, or Liver Metastases

Who this might be right for
Colorectal CancerHead and Neck CancerMetastatic Cancer
European Organisation for Research and Treatment of Cancer - EORTC 27
Early research (Phase 1)Study completedNCT01204476
What this trial is testing

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

Who this might be right for
Gastrin-Producing Neuroendocrine TumorLung Carcinoid TumorMetastatic Digestive System Neuroendocrine Tumor G1+12 more
National Cancer Institute (NCI) 27